Some evidence suggests that isoflurane metabolism to trifluoroacetic acid and inorganic fluoride by human liver microsomes in vitro is catalyzed by cytochrome P450 2E1 (CYP2E1). This investigation tested the hypothesis that P450 2E1 predominantly catalyzes human isoflurane metabolism in vivo. Disulfiram, which is converted in vivo to a selective inhibitor of P450 2E1, was used as a metabolic probe for P450 2E1.


Twenty-two elective surgery patients who provided institutionally-approved written informed consent were randomized to receive disulfiram (500 mg orally, N = 12) or nothing (controls, N = 10) the evening before surgery. All patients received a standard isoflurane anesthetic (1.5% end-tidal in oxygen) for 8 hr. Urine and plasma trifluoroacetic acid and fluoride concentrations were quantitated in samples obtained for 4 days postoperatively.


Patient groups were similar with respect to age, weight, gender, duration of surgery, blood loss, and delivered isoflurane dose, measured by cumulative end-tidal isoflurane concentrations (9.7-10.2 MAC-hr). Postoperative urine excretion of trifluoroacetic acid (days 1-4) and fluoride (days 1-3) was significantly (P<0.05) diminished in disulfiram-treated patients. Cumulative 0-96 hr excretion of trifluoroacetic acid and fluoride in disulfiram-treated patients was 34+/-72 and 270+/-70 micromoles (mean +/- SD), respectively, compared to 440+/-360 and 1500+/-800 micromoles in controls (P<0.05 for both). Disulfiram also abolished the rise in plasma metabolite concentrations.


Disulfiram, a selective inhibitor of human hepatic P450 2E1, prevented 80-90% of isoflurane metabolism. These results suggest that P450 2E1 is the predominant P450 isoform responsible for human clinical isoflurane metabolism in vivo.

ISOFLURANE is metabolized by human hepatic cytochrome P450 to a reactive acyl halide metabolite [1]capable of trifluoroacetylating liver proteins. [2]These react with antitrifluoroacetylated protein antibodies, formed after previous exposure to trifluoroacetylating anesthetics, potentially resulting in immune-mediated hepatic necrosis. [3-5]These protein antigens are analogous to those which form after halothane, [6,7]and immune-mediated isoflurane hepatitis appears similar to that which occurs more frequently after halothane. [8,9]Other, stable metabolites of isoflurane include trifluoroacetic acid and inorganic fluoride. Compared with halothane and enflurane, which also undergo bioactivation to trifluoroacetylating metabolites, the incidence of immune-mediated hepatic necrosis after isoflurane is quite rare, owing to the comparatively slower rate of isoflurane metabolism and more rapid isoflurane excretion which together combine to limit the overall extent of isoflurane metabolism to approximately 0.2-1%. [10]Nevertheless, factors potentially influencing isoflurane metabolism remain elusive.

Identification of P450 isoforms responsible for anesthetic metabolism has provided mechanistic insights into interindividual variability in drug disposition, the biochemical basis for drug toxification, drug interactions, and potential interventions to diminish or prevent toxicity. [11-14]Previous investigations have identified P450 2E1 as the predominant P450 responsible for metabolizing methoxyflurane, enflurane, sevoflurane, and halothane in human liver microscomes in vitro. [15,16]Corroborating clinical investigations have shown P450 2E1 to be a predominant isoform catalyzing human enflurane, sevoflurane, and halothane metabolism in vivo. [12-14] 

Elucidation of the P450 isoform catalyzing human isoflurane metabolism remains incomplete. Microsomal studies implicating P450 2E1 in vitro used only isoform-selective inhibitors, but could not correlate metabolism with P450 2E1 content, due to the low rates of isoflurane metabolism. [16]Increased isoflurane metabolism in vivo in patients taking isoniazid also implicated P450 2E1 participation, although these were uncontrolled case reports. [17]Single-dose disulfiram inhibition of human P450 2E1 activity in vivo [18]has been utilized previously as an effective probe for identifying participation of this isoform in volatile anesthetic metabolism. [12-14]Disulfiram and its primary metabolite diethyldithiocarbamate are selective mechanism-based inhibitors of human liver microsomal P450 2E1 in vitro. [19]This investigation tested the hypothesis that cytochrome P450 2E1 catalyzes isoflurane metabolism in humans in vivo.

Materials and Methods

Twenty-two patients undergoing anesthesia for elective surgery were studied after providing written informed consent. The investigational protocol was approved by the Institutional Human Subjects Committee. Patient selection criteria and protocol were similar to those used previously. [12-14]Briefly, subjects were within 30% of ideal body weight, had no history of hepatic or renal insufficiency, ethanol abuse, or current use of medications known to alter hepatic drug metabolism, and were undergoing peripheral (i.e., no thoracic or abdominal) surgical procedures of anticipated 8-10 hr duration. Patients were randomized to receive disulfiram 500 mg orally at bedtime on the evening before surgery (N = 12), or nothing (controls; N = 10).

All patients received a standardized anesthetic designed to minimize potential drug interactions other than the desired test interaction. Anesthesia was induced with propofol (1-2.5 mg/kg), fentanyl (50-100 [micro sign]g), and succinylcholine, followed by tracheal intubation, and thereafter maintained with isoflurane (1.5% end-tidal target concentration; 1.3 MAC) for 8 hr, unless the surgical procedure ended before that time. Inspired and end-tidal enflurane concentrations (Capnomac, Datex Medical Instrumentation, Tewksbury, MA) were recorded at 15 min intervals while patients were intubated. For operations lasting longer than 8 hr, isoflurane was discontinued after 8 hr and anesthesia was maintained with propofol, nitrous oxide, and fentanyl. Anesthetic dose was calculated as the product of end-tidal isoflurane concentration (MAC = 1.15%, uncorrected for age) and time, determined in 15 min intervals, which were summed to obtain total isoflurane exposure, expressed as MAC-hr.

Venous samples for determination of blood isoflurane concentration were obtained prior to induction, and at intervals for 24 hr after the start of isoflurane. Samples were frozen at -20 [degree sign]C, and isoflurane concentrations measured by gas chromatography as described. [12,20]Venous samples for determination of plasma trifluoroacetic acid and fluoride concentration was obtained prior to induction, and periodically for 96 hr after the start of isoflurane anesthesia. Samples were frozen at -20 [degree sign]C until analysis. Urine for determination of trifluoroacetic acid and fluoride concentration was obtained for four consecutive 24 hr intervals beginning at the start of anesthesia. Urine was thoroughly mixed, the volume was measured, and an aliquot frozen at -20 [degree sign]C for later analysis. Trifluoroacetic acid concentrations were determined by ion chromatography and fluoride was measured by ion-selective electrode, with limits of quantification of 1 and 2 [micro sign]M, respectively, as described previously. [12,21] 

Patient demographic data and peak plasma fluoride concentrations, were analyzed by Student's unpaired t-test. Urine trifluoroacetic acid and fluoride excretion in the two groups were compared by repeated measures analysis of variance. Data were analyzed using SigmaStat (SPSS Inc., Chicago, IL). Results are expressed as the mean +/− standard deviation.


Patient demographic data are provided in Table 1. Control and disulfiram-treated groups were similar with respect to age, weight, gender, and duration of surgery, as well as blood loss (not shown). The dose of isoflurane delivered, determined from end-tidal isoflurane concentrations, was also similar in both groups. Isoflurane dose during the 8 hr period of anesthetic delivery was 10.2 +/− 1.1 and 9.7 +/− 1.2 MAC-hr in controls and disulfiram-treated patients, respectively, while total dose during the entire anesthetic period was 10.8 +/− 1.1 and 10.1 +/− 1.3 MAC-hr. Blood isoflurane concentrations (approximately 300 [micro sign]M) were not significantly different in controls and disulfiram-treated patients, further confirming equivalency of isoflurane dose.

Table 1. Patient Demographics and Anesthetic Exposure

Table 1. Patient Demographics and Anesthetic Exposure
Table 1. Patient Demographics and Anesthetic Exposure

The pattern and time course of isoflurane metabolites plasma concentration and urinary excretion were consistent with previous reports. [10,22]Average urine fluoride excretion diminished after postoperative day 2, while trifluoroacetic acid elimination was more constant (Figure 1). Plasma trifluoroacetic acid and fluoride concentrations in a representative control patient are shown in Figure 2. Fluoride concentrations were higher than those after 1-3 MAC-hr isoflurane. [22,23] 

Figure 1. Postoperative urine fluoride (A) and trifluoroacetic acid (B) excretion (mean +/− SD) in control (open bars) and disulfiram-treated (closed bars) patients. *P < 0.05 versus controls.

Figure 1. Postoperative urine fluoride (A) and trifluoroacetic acid (B) excretion (mean +/− SD) in control (open bars) and disulfiram-treated (closed bars) patients. *P < 0.05 versus controls.

Figure 2. Plasma fluoride (A) and trifluoroacetic acid (B) concentrations in a typical control (open circles) and disulfiram-treated (closed circles) patient. Isoflurane was administered from 0-8 hr.

Figure 2. Plasma fluoride (A) and trifluoroacetic acid (B) concentrations in a typical control (open circles) and disulfiram-treated (closed circles) patient. Isoflurane was administered from 0-8 hr.

Disulfiram pretreatment markedly inhibited isoflurane metabolism, assessed by urine excretion of trifluoroacetic acid and fluoride (Figure 1). In disulfiram treated patients, daily excretion of trifluoroacetic acid and fluoride were significantly diminished on postoperative days 1-4 compared with controls. Trifluoroacetic acid in urine was undetectable on day 1 in 8/12 disulfiram-treated patients, and excretion was 1.5 +/− 2.7 [micro sign]moles, compared with 90 +/− 150 [micro sign]moles in controls. Cumulative 0-96 hr excretion of trifluoroacetic acid and fluoride in disulfiram-treated patients was 34 +/− 72 and 270 +/− 70 [micro sign]moles, respectively, compared to 440 +/− 360 and 1500 +/− 800 [micro sign]moles in controls (P < 0.05 for both).

Disulfiram treatment abolished the rise in plasma trifluoroacetic acid and fluoride concentration following isoflurane administration. Results for representative control and disulfiram patients are shown in Figure 2.


Patient pretreatment with a single disulfiram dose the night before surgery markedly inhibited isoflurane metabolism, as evidenced by substantial reductions in urine trifluoroacetic acid and fluoride excretion, and plasma metabolite concentrations. Cumulative 0-96 hr urinary metabolite excretion was inhibited 82-93%, and plasma metabolite area under the concentration-time curve was diminished more than 90%, compared with controls. Urine collection for additional postoperative days would likely have shown a greater degree of inhibition, due to more complete metabolite recovery, particularly in controls. Disulfiram effects were not attributable to differences in isoflurane dose, which was similar in both groups. Rather, differences between groups were due to disulfiram inhibition of isoflurane metabolism. Disulfiram inhibition of isoflurane metabolism strongly suggests that P450 2E1 is the predominant P450 isoform catalyzing human isoflurane metabolism in vivo.

Single-dose disulfiram has previously been demonstrated to be an effective inhibitor of human P450 2E1 activity in vivo. [18]Oral disulfiram (500 mg) administered 10 hr prior to chlorzoxazone, a specific noninvasive probe of hepatic P450 2E1 activity, [24]significantly diminished P450 2E1 activity in vivo evidenced by an 85% decrease in chlorzoxazone 6-hydroxylation. Disulfiram inhibition of human P450 2E1 in vivo was subsequently used to probe and identify P450 2E1 participation in the metabolism of enflurane, sevoflurane and halothane in humans in vivo, and to diminish the P450 2E1-mediated toxification of halothane. [12-14]Based on urinary metabolite excretion, disulfiram inhibited metabolism of chlorzoxazone 93%, enflurane 89%, halothane 84-91%, isoflurane 82-93%, and sevoflurane 73-80%. Thus P450 2E1 is the predominant isoform which metabolizes halothane, enflurane, isoflurane, and sevoflurane in humans in vivo.

When we previously reported disulfiram reductions of enflurane, sevoflurane and halothane metabolism in humans in vivo, [12-14]the effectiveness of disulfiram inhibition of P450 2E1 activity in vivo had been clearly demonstrated, [18]however, disulfiram specificity toward only P450 2E1 was unknown. Specifically, owing to overlapping substrate specificities of P450 2E1 and 2A6, [25-28]and reports of disulfiram metabolite inhibition of human P450 2A6 in vitro, [25,29,30]it could not be unambiguously established that disulfiram inhibition of anesthetic metabolism represented only P450 2E1-mediated activity, particularly to the exclusion of P450 2A6.

Recent clinical investigations have determined, however, that single-dose disulfiram does exhibit selectivity for P450 2E1 in vivo. Disulfiram did not inhibit human P450 2A6 activity, assessed by the P450 2A6 probe coumarin. [31]Urine 7-hydroxycoumarin excretion was unchanged by single-dose disulfiram, [31]administered using the same protocol as in the present and previous investigations of anesthetic metabolism. Furthermore, additional clinical evaluations have recently shown that disulfiram does not significantly inhibit human P450 2C9, 2C19, 2D6, and 3A4 activities in vivo. [Section] Together with 2E1, these isoforms comprise the majority (approximately 60%) of total human hepatic P450s (of which 73% have been identified). [32]Thus it is apparent that single-dose disulfiram inhibition of drug metabolism is selective toward P450 2E1. Disulfiram inhibition of isoflurane metabolism in the present investigation, and that of enflurane, sevoflurane, and halothane in previous investigations, [12-14]suggests that P450 2E1 is the predominant isoform responsible for metabolism of these volatile anesthetics in humans in vivo.

A characteristic yet previously unexplained feature of single-dose disulfiram inhibition of volatile anesthetic metabolism has been marked inhibition of plasma metabolite appearance and urinary excretion immediately postoperatively, with small increases on postoperative days 3 and 4. [12-14]It is now apparent that this represents resynthesis of P450 2E1 after 48-72 hr. [33]In a recent clinical investigation, P450 2E1 activity was probed by chlorzoxazone clearance and 6-hydroxychlorzoxazone formation clearance before, and 1, 3, 6, 8, 10, and 13 days after disulfiram. [33]P450 2E1 activity returned with a half-life of 32 hr, and was complete after 8 days. Return of activity was attributed to enzyme resynthesis, rather than prolonged elimination of disulfiram or its metabolites. Thus metabolite appearance after 3-4 days in disulfiram-treated patients suggests prolonged low-level anesthetic residence and resynthesis of P450 2E1, as observed with enflurane, halothane, sevoflurane, [12-14]and now isoflurane. If greater inhibition of metabolite formation is desired, a second disulfiram dose should be administered two days postoperatively.

Identification of P450 isoforms responsible for human anesthetic metabolism rests on several approaches. In vitro techniques include (1) metabolism by human cDNA-expressed isoforms, inhibition of microsomal metabolism by (2) isoform-selective antibodies and/or (3) chemical inhibitors, and correlation of drug metabolism with the (4) activity, or (5) protein content of specific isoforms in microsomes from a population of human livers (or other tissues) with varying isoform activities (due to genetic variation, enzyme induction and/or enzyme inhibition). In vivo methods include inhibition of metabolism by drugs which are isoform-selective inhibitors, induction of metabolism, and correlation of metabolism with the hepatic activity or protein content of specific P450s in a population of humans. Our identification of P450 2E1 participation in in vitro human liver microsomal enflurane, methoxyflurane, sevoflurane, and halothane metabolism was based on approaches 1 and 3-5 above, however, only method 3 could be used to implicate P450 2E1 in isoflurane metabolism due to the low rate of isoflurane metabolism. [15,16,20,34]The present clinical investigation corroborates this in vitro implication, and more firmly identifies the role of P450 2E1 in human isoflurane metabolism. Isoflurane metabolism by P450 2E1 explains greater metabolism in patients taking isoniazid, [17]which induces P450 2E1 activity. [35,36]Chronic ethanol consumption also induces P450 2E1 in vivo, [37]increases rat liver microsomal isoflurane metabolism in vitro, [38]and would be expected to enhance isoflurane metabolism in humans. In vitro-in vivo correlations have thus been firmly established for human volatile anesthetic metabolism by P450.

Immune-mediated hepatic necrosis due to isoflurane metabolism and hepatic protein trifluoroacetylation is rare, presumably due to the limited extent of isoflurane metabolism and protein adduction. [2,10]One report, in a patient taking phenytoin, suggested that enzyme induction by phenytoin contributed to isoflurane toxicity, and that patients taking any drug which induces P450 are at increased risk for hepatotoxicity. [5]This attribution and warning are questionable, however, since phenytoin is not known to induce human P450 2E1, the number of P450 2E1 inducers is small, and enzyme induction was not a risk for hepatitis after isoflurane. [3] 

In summary, P450 2E1 appears to be the predominant cytochrome P450 isoform responsible for clinical isoflurane metabolism in humans.

We appreciate the assistance of the various anesthesiologists, anesthesiology residents and nursing personnel who participated in this investigation.

[Section] Single-dose disulfiram had no effect on the activity of P450s 2C9, 2C19, 2D6 or 3A4 in humans, assessed by tolbutamide, mephenytoin and dextromethorphan metabolism, and midazolam clearance, respectively (E.D. Kharasch, manuscript in preparation).


Bradshaw JJ, Ivanetich KM: Isoflurane: A comparison of its metabolism by human and rat hepatic cytochrome P-450. Anesth Analg 1984; 63:805-13
Christ DD, Satoh H, Kenna JG, Pohl LR: Potential metabolic basis for enflurane hepatitis and the apparent cross-sensitization between enflurane and halothane. Drug Metab Dispos 1988; 16:135-40
Stoelting RK, Blitt CD, Cohen PJ, Merin RG: Hepatic dysfunction after isoflurane anesthesia. Anesth Analg 1987; 66:147-53
Gunza JT, Pashayan AG: Postoperative elevation of serum transaminases following isoflurane anesthesia. J Clin Anesth 1992; 4:336-41
Sinha A, Clatch RJ, Stuck G, Blumenthal SA, Patel SA: Isoflurane hepatotoxicity: A case report and review of the literature. Am J Gastroenterol 1996; 91:2406-9
Kenna JG, Neuberger J, Williams R: Evidence for expression in human liver of halothane-induced neoantigens by antibodies in sera from patients with halothane hepatitis. Hepatology 1988; 8:1635-41
Ilyin GP, Rissel M, Malledant Y, Tanguy M, Guillouzo A: Human hepatocytes express trifluoroacetylated neoantigens after in vitro exposure to halothane. Biochem Pharmacol 1994; 48:561-7
Ray DC, Drummond GB: Halothane hepatitis. Br J Anaesth 1991; 67:84-99
Gut J, Christen U, Huwyler J: Mechanisms of halothane toxicity: Novel insights. Pharmacol Ther 1993; 58:133-55
Davidkova T, Kikuchi H, Fujii K, Mukaida K, Sato N, Kawachi S, Morio M: Biotransformation of isoflurane: Urinary and serum fluoride ion and organic fluorine. Anesthesiology 1988; 69:218-22
Kharasch ED, Russell M, Mautz D, Thummel KE, Kunze KL, Bowdle TA, Cox K: The role of cytochrome P450 3A4 in alfentanil clearance: Implications for interindividual variability in disposition and perioperative drug interactions. Anesthesiology 1997; 87:36-50
Kharasch ED, Thummel KE, Mautz D, Bosse S: Clinical enflurane metabolism by cytochrome P450 2E1. Clin Pharmacol Ther 1994; 55:434-40
Kharasch ED, Armstrong AS, Gunn K, Artru A, Cox K: Clinical sevoflurane metabolism and disposition: II. The role of cytochrome P450 2E1 in fluoride and hexafluoroisopropanol formation. Anesthesiology 1995; 82:1379-88
Kharasch ED, Hankins D, Mautz D, Thummel KE: Identification of the enzyme responsible for oxidative halothane metabolism: Implications for prevention of halothane hepatitis. Lancet 1996; 347:1367-71
Thummel KE, Kharasch ED, Podoll T, Kunze K: Human liver microsomal enflurane defluorination catalyzed by cytochrome P-450 2E1. Drug Metab Dispos 1993; 21:350-7
Kharasch ED, Thummel KE: Identification of cytochrome P450 2E1 as the predominant enzyme catalyzing human liver microsomal defluorination of sevoflurane, isoflurane and methoxyflurane. Anesthesiology 1993; 79:795-807
Gauntlett IS, Koblin DD, Fahey MR, Konopka K, Greunke LD, Waskell L, Eger EI II: Metabolism of isoflurane in patients receiving isoniazid. Anesth Analg 1989; 69:245-9
Kharasch ED, Thummel K, Mhyre J, Lillibridge J: Single-dose disulfiram inhibition of chlorzoxazone metabolism: A clinical probe for P450 2E1. Clin Pharmacol Ther 1993; 53:643-50
Guengerich FP, Kim D-H, Iwasaki M: Role of human P-450 IIE1 in the oxidation of many low molecular weight cancer suspects. Chem Res Toxicol 1991; 4:168-79
Spracklin D, Hankins DC, Fisher JM, Thummel KE, Kharasch ED: Cytochrome P450 2E1 is the principal catalyst of human oxidative halothane metabolism. J Pharmacol Exp Ther 1997; 281:400-11
Hankins DC, Kharasch ED: Determination of the halothane metabolites trifluoroacetic acid and bromide in plasma and urine by ion chromatography. J Chromatogr B 1997; 692: 413-8
Holaday DA, Fiserova-Bergerova V, Latto IP, Zumbiel MA: Resistance of isoflurane to biotransformation in man. Anesthesiology 1975; 43:325-32
Mazze RI, Cousins MJ, Barr GA: Renal effects and metabolism of isoflurane in man. Anesthesiology 1974; 40:536-42
Peter R, Bocker R, Beaune PH, Iwasaki M, Guengerich FP, Yang CS: Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450IIE1. Chem Res Toxicol 1990; 3:565-73
Yamazaki H, Inui Y, Yun C-H, Guengerich FP, Shimada T: Cytochrome P450 2E1 and 2A6 enzymes as major catalysts for metabolic activation of N-nitrosodialkylamines and tobacco-related nitrosamines in human liver microsomes. Carcinogenesis 1992; 13:1789-94
Camus A-M, Geneste O, Honkakoski P, Bereziat J-C, Henderson CJ, Wolf CR, Bartsch H, Lang MA: High variability of nitrosamine metabolism among individuals: Role of cytochromes P450 2A6 and 2E1 in the dealkylation of N-nitrosodimethylamine and N-nitrosodiethylamine in mice and humans. Mol Carcinogen 1993; 7:268-75
Duescher RJ, Elfarra AA: Human liver microsomes are efficient catalysts of 1,3-butadiene oxidation: Evidence for major roles by cytochromes P450 2A6 and 2E1. Arch Biochem Biophys 1994; 311:342-9
Tiano HF, Hosokawa M, Chulada PC, Smith PB, Wang R-L, Gonzalez FJ, Crespi CL, Langenbach R: Retroviral mediated expression of human cytochrome P4502A6 in C3H/10T1/2 cells confers transformability by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK). Carcinogenesis 1993; 14:1421-7
Chang TKH, Gonzalez FJ, Waxman DJ: Evaluation of triacetyloleandomycin, [small alpha, Greek]-naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450. Arch Biochem Biophys 1994; 311:437-42
Ono S, Hatanaka T, Hotta H, Satoh T, Gonzalez FJ, Tsutsui M: Specificity of substrate and inhibitor probes for cytochrome P450s: Evaluation of in vitro metabolism using cDNA-expressed human P450s and human liver microsomes. Xenobiotica 1996; 26: 681-93
Kharasch ED, Hankins DC, Baxter PJ, Thummel KE: Single-dose disulfiram does not inhibit CYP2A6 activity. Clin Pharmacol Ther 1998; 64:39-45
Guengerich FP: Human cytochrome P450 enzymes, Cytochrome P450: Structure, Mechanism and Biochemistry. Edited by Ortiz de Montellano PR. New York, Plenum Press, 1995, pp 473-535
Emery MG, Jubert C, Thummel KE, Kharasch ED: Using disulfiram, a mechanism based inhibitor, and chloroxazone to assess in vivo resynthesis of CYP2E1 in humans. Proceedings of the 12th International Symposium on Microsomes and Drug Oxidations; July 1998; Montpellier, France, p. 288
Kharasch ED, Hankins DC, Thummel KE: Human kidney methoxyflurane and sevoflurane metabolism: Intrarenal fluoride production as a possible mechanism of methoxyflurane nephrotoxicity. Anesthesiology 1995; 82:689-99
Zand R, Nelson SD, Slattery JT, Thummel KE, Kalhorn TF, Adams SP, Wright JM: Inhibition and induction of cytochrome P4502E1-catalyzed oxidation by isoniazid in humans. Clin Pharmacol Ther 1993; 54:142-9
O'Shea D, Kim RB, Wilkinson GR: Modulation of CYP2E1 activity by isoniazid in rapid and slow N-acetylators. Br J Clin Pharmacol 1997; 43:99-103
Chien JY, Thummel KE, Slattery JT: Pharmacokinetic consequences of induction of CYP2E1 by ligand stabilization. Drug Metab Dispos 1997; 25:1165-74
Dan Dyke RA: Enflurane, isoflurane, and methoxyflurane metabolism in rat hepatic microsomes from ethanol-treated animals. Anesthesiology 1983; 58:221-4